Interim Clinical Considerations for COVID-19 Treatment in Outpatients
The United States government is ending its current ordering of COVID-19 oral antiviral treatments. Ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir (Lagevrio) began transitioning to the commercial market on November 1, 2023, with anticipated completion on December 31, 2023. Ritonavir-boosted nirmatrelvir and molnupiravir will continue to be available during and after this transition to all eligible patients, including low and no-cost access for patients who are underinsured, uninsured, and who are on Medicare or Medicaid. All providers should ensure that they order sufficient product from the United States Government starting November 1, 2023, to meet expected demand during the transition. Providers and clinicians should review the commercialization transition guide for information on ordering and distribution timelines and patient assistance programs.